Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Lyell Immunopharma (NASDAQ:LYEL) from a strong sell rating to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports.

LYEL has been the subject of a number of other research reports. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Lyell Immunopharma in a research note on Thursday, May 7th. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Finally, Citizens Jmp initiated coverage on shares of Lyell Immunopharma in a report on Monday, March 9th. They issued a “market outperform” rating and a $34.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Price Performance

LYEL opened at $16.13 on Monday. The company’s 50 day simple moving average is $21.40 and its two-hundred day simple moving average is $23.58. Lyell Immunopharma has a 1-year low of $7.65 and a 1-year high of $45.00. The firm has a market capitalization of $376.31 million, a price-to-earnings ratio of -1.17 and a beta of -0.05.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, meeting the consensus estimate of ($1.10). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. On average, equities analysts anticipate that Lyell Immunopharma will post -8.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its position in shares of Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares during the last quarter. Marshall Wace LLP acquired a new position in Lyell Immunopharma during the 2nd quarter valued at about $94,000. Bridgeway Capital Management LLC acquired a new position in Lyell Immunopharma during the 2nd quarter valued at about $159,000. BBR Partners LLC acquired a new position in Lyell Immunopharma during the 4th quarter valued at about $210,000. Finally, Walleye Capital LLC acquired a new stake in shares of Lyell Immunopharma in the 2nd quarter worth approximately $258,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.